Clinical Epigenetics (Jun 2023)
Identifying primary and secondary MLH1 epimutation carriers displaying low-level constitutional MLH1 methylation using droplet digital PCR and genome-wide DNA methylation profiling of colorectal cancers
- Jihoon E. Joo,
- Khalid Mahmood,
- Romy Walker,
- Peter Georgeson,
- Ida Candiloro,
- Mark Clendenning,
- Julia Como,
- Sharelle Joseland,
- Susan Preston,
- Lise Graversen,
- Mathilda Wilding,
- Michael Field,
- Michelle Lemon,
- Janette Wakeling,
- Helen Marfan,
- Rachel Susman,
- Joanne Isbister,
- Emma Edwards,
- Michelle Bowman,
- Judy Kirk,
- Emilia Ip,
- Lynne McKay,
- Yoland Antill,
- John L. Hopper,
- Alex Boussioutas,
- Finlay A. Macrae,
- Alexander Dobrovic,
- Mark A. Jenkins,
- Christophe Rosty,
- Ingrid M. Winship,
- Daniel D. Buchanan
Affiliations
- Jihoon E. Joo
- Colorectal Oncogenomics Group, Department of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of Melbourne
- Khalid Mahmood
- Colorectal Oncogenomics Group, Department of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of Melbourne
- Romy Walker
- Colorectal Oncogenomics Group, Department of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of Melbourne
- Peter Georgeson
- Colorectal Oncogenomics Group, Department of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of Melbourne
- Ida Candiloro
- Beacon Biomarkers Lab, Department of Surgery, Austin Health, University of Melbourne
- Mark Clendenning
- Colorectal Oncogenomics Group, Department of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of Melbourne
- Julia Como
- Colorectal Oncogenomics Group, Department of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of Melbourne
- Sharelle Joseland
- Colorectal Oncogenomics Group, Department of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of Melbourne
- Susan Preston
- Colorectal Oncogenomics Group, Department of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of Melbourne
- Lise Graversen
- Department of Clinical Genetics, Aarhus University Hospital
- Mathilda Wilding
- Department of Clinical Genetics, Royal North Shore Hospital
- Michael Field
- Department of Clinical Genetics, Royal North Shore Hospital
- Michelle Lemon
- Genetic Health Queensland, Royal Brisbane and Women’s Hospital
- Janette Wakeling
- Genetic Health Queensland, Royal Brisbane and Women’s Hospital
- Helen Marfan
- Genetic Health Queensland, Royal Brisbane and Women’s Hospital
- Rachel Susman
- Genetic Health Queensland, Royal Brisbane and Women’s Hospital
- Joanne Isbister
- Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital
- Emma Edwards
- Familial Cancer Service, Crown Princess Mary Cancer Centre, Westmead Hospital
- Michelle Bowman
- Familial Cancer Service, Crown Princess Mary Cancer Centre, Westmead Hospital
- Judy Kirk
- Familial Cancer Service, Crown Princess Mary Cancer Centre, Westmead Hospital
- Emilia Ip
- Department of Cancer Genetics, Liverpool Hospital
- Lynne McKay
- The Cabrini Family Cancer Clinic, Cabrini Health
- Yoland Antill
- Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital
- John L. Hopper
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne
- Alex Boussioutas
- Department of Gastroenterology, The Alfred Hospital
- Finlay A. Macrae
- Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital
- Alexander Dobrovic
- Beacon Biomarkers Lab, Department of Surgery, Austin Health, University of Melbourne
- Mark A. Jenkins
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne
- Christophe Rosty
- Colorectal Oncogenomics Group, Department of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of Melbourne
- Ingrid M. Winship
- Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital
- Daniel D. Buchanan
- Colorectal Oncogenomics Group, Department of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of Melbourne
- DOI
- https://doi.org/10.1186/s13148-023-01511-y
- Journal volume & issue
-
Vol. 15,
no. 1
pp. 1 – 17
Abstract
Abstract Background MLH1 epimutation is characterised by constitutional monoallelic MLH1 promoter hypermethylation, which can cause colorectal cancer (CRC). Tumour molecular profiles of MLH1 epimutation CRCs were used to classify germline MLH1 promoter variants of uncertain significance and MLH1 methylated early-onset CRCs (EOCRCs). Genome-wide DNA methylation and somatic mutational profiles of tumours from two germline MLH1: c.-11C > T and one MLH1: c.-[28A > G; 7C > T] carriers and three MLH1 methylated EOCRCs ( T carriers and MLH1 methylated EOCRCs clustered with the constitutional MLH1 epimutation CRCs but not with the sporadic MLH1 methylated CRCs. Furthermore, monoallelic MLH1 methylation and APC promoter hypermethylation in tumour were observed in both MLH1 epimutation and germline MLH1: c.-11C > T carriers and MLH1 methylated EOCRCs. Mosaic constitutional MLH1 methylation in MLH1: c.-11C > T carriers and 1 of 3 MLH1 methylated EOCRCs was identified by methylation-sensitive ddPCR. Conclusions Mosaic MLH1 epimutation underlies the CRC aetiology in MLH1: c.-11C > T germline carriers and a subset of MLH1 methylated EOCRCs. Tumour profiling and ultra-sensitive ddPCR methylation testing can be used to identify mosaic MLH1 epimutation carriers.
Keywords
- MLH1 epimutation
- Genome wide DNA methylation
- MLH1 methylation
- MMR deficiency
- Colorectal cancer
- Lynch syndrome